ArticleTrends in genetics : TIG2010
X-linked tumor suppressors: perplexing inheritance, a unique therapeutic opportunity.
Article in Trends in genetics : TIG, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Review
- Sex-specific familial aggregation of cancers in Finland.Scientific reports · 2022Article
- Review
- The X-linked tumor suppressor TSPX downregulates cancer-drivers/oncogenes in prostate cancer in a C-terminal acidic domain dependent manner.Oncotarget · 2019Article
- Article
- Deciphering the Role of the Barr Body in Malignancy: An insight into head and neck cancer.Sultan Qaboos University medical journal · 2017Review
- Increased expression of long non-coding RNA XIST predicts favorable prognosis of cervical squamous cell carcinoma subsequent to definitive chemoradiation therapy.Oncology letters · 2016Article
- Guided by RNAs: X-inactivation as a model for lncRNA function.Journal of molecular biology · 2013Review
- IPEX Syndrome, FOXP3 and Cancer.Journal of syndromes · 2013Article
- FOXP3 regulates sensitivity of cancer cells to irradiation by transcriptional repression of BRCA1.Cancer research · 2013Article
- FOXP3: genetic and epigenetic implications for autoimmunity.Journal of autoimmunity · 2013Review
- Inactivation of X-linked tumor suppressor genes in human cancer.Future oncology (London, England) · 2012Review
- Article
- FOXP3 orchestrates H4K16 acetylation and H3K4 trimethylation for activation of multiple genes by recruiting MOF and causing displacement of PLU-1.Molecular cell · 2011Article
- Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers.Cancer research · 2011Article
- The X-linked tumor suppressor TSPX interacts and promotes degradation of the hepatitis B viral protein HBx via the proteasome pathway.PloS one · 2011Article
- Signalling through FOXP3 as an X-linked tumor suppressor.The international journal of biochemistry & cell biology · 2010Review
- Cancer Comprehensive Analysis in Gastric Carcinoma: Benefits and New Perspectives.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Unlike autosomal genes, the majority of X-linked genes are subject to dosage compensation. As a result, female tissues comprise cells exclusively expressing X-linked genes from one or other parent. The implication of having only one allele of active X-linked genes in cancer pathogenesis, i.e. somatic single-hit inactivation and dominant inheritance, has not been extensively explored. Recent studies have identified FOXP3 and WTX as two X-linked tumor suppressor genes that are somatically inactivated by single genetic hits. Because the predicted dominant inheritance of cancer risk has not been demonstrated in humans, we will discuss the possible conditions that might prevent such dominant inheritance. We also argue that the existence of a genetically intact allele in cancer cells in women, together with apparent abnormal X inactivation in cancer cells, might provide an opportunity to selectively reactivate tumor suppressor genes for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.